Suggested Citation:
"Appendix B: Speaker Biographies." Institute of Medicine. 2008. Addressing the Barriers to Pediatric Drug Development: Workshop Summary. Washington, DC: The National Academies Press.
doi: 10.17226/11911.
Suggested Citation:
"Appendix B: Speaker Biographies." Institute of Medicine. 2008. Addressing the Barriers to Pediatric Drug Development: Workshop Summary. Washington, DC: The National Academies Press.
doi: 10.17226/11911.
Suggested Citation:
"Appendix B: Speaker Biographies." Institute of Medicine. 2008. Addressing the Barriers to Pediatric Drug Development: Workshop Summary. Washington, DC: The National Academies Press.
doi: 10.17226/11911.
Suggested Citation:
"Appendix B: Speaker Biographies." Institute of Medicine. 2008. Addressing the Barriers to Pediatric Drug Development: Workshop Summary. Washington, DC: The National Academies Press.
doi: 10.17226/11911.
Suggested Citation:
"Appendix B: Speaker Biographies." Institute of Medicine. 2008. Addressing the Barriers to Pediatric Drug Development: Workshop Summary. Washington, DC: The National Academies Press.
doi: 10.17226/11911.
Suggested Citation:
"Appendix B: Speaker Biographies." Institute of Medicine. 2008. Addressing the Barriers to Pediatric Drug Development: Workshop Summary. Washington, DC: The National Academies Press.
doi: 10.17226/11911.
Suggested Citation:
"Appendix B: Speaker Biographies." Institute of Medicine. 2008. Addressing the Barriers to Pediatric Drug Development: Workshop Summary. Washington, DC: The National Academies Press.
doi: 10.17226/11911.
Subscribe to Email from the National Academies
Keep up with all of the activities, publications, and events by subscribing to free updates by email.
Mobile Navigation
Addressing the Barriers to Pediatric Drug Development: Workshop Summary
2008
Decades of research have demonstrated that children do not respond to medications in the same way as adults. Differences between children and adults in the overall response to medications are due to profound anatomical, physiological, and developmental differences. Although few would argue that children should receive medications that have not been adequately tested for safety and efficacy, the majority of drugs prescribed for children—50 to 75 percent—have not been tested in pediatric populations. Without adequate data from such testing, prescribing drugs appropriately becomes challenging for clinicians treating children, from infancy through adolescence. Addressing the Barriers to Pediatric Drug Development is the summary of a workshop, held in Washington, D.C. on June 13, 2006, that was organized to identify barriers to the development and testing of drugs for pediatric populations, as well as ways in which the system can be improved to facilitate better treatments for children.
Sign in to access your saved publications, downloads, and email
preferences.
Former MyNAP users: You'll need to reset your password on your first
login to MyAcademies. Click "Forgot password" below to receive a reset
link via email. Having trouble?
Visit our FAQ page
to contact support.
Members of the National Academy of Sciences, National Academy of
Engineering, or National Academy of Medicine should log in through their
respective Academy portals.
Register
Register
Thank You
Thank You
Thank you for creating a MyAcademies account!
Enjoy free access to thousands of National Academies' publications, a
10% discount off every purchase, and build your personal library.
Forgot Password
Forgot Password
Enter the email address for your MyAcademies (formerly MyNAP) account to
receive password reset instructions.
Reset Requested
Reset Requested
We sent password reset instructions to
your email
. Follow the link in that email to create a new password. Didn't receive
it? Check your spam folder or
contact us
for assistance.
We sent a verification link to your email. Please check your inbox (and
spam folder) and follow the link to verify your email address. If you
did not receive the email, you can request a new verification link below